Clinical trial
Effect of HIV Protease Inhibitor Drugs on Glucose and Insulin Metabolism
NCT00135434 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00135434 |
|---|---|
| Title | Effect of HIV Protease Inhibitor Drugs on Glucose and Insulin Metabolism |
| Official title | Effect of HIV Protease Inhibitor Drugs on Glucose and Insulin Metabolism |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Atazanavir/Ritonavir/Lopinavir/ritonavir |
| Enrollment | 25 |
| Start date | Sep 1, 2004 |
| Primary completion | Jun 1, 2005 |
| Completion | Jun 1, 2005 |
| First posted | Aug 26, 2005 |
| Last update posted | Apr 8, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: